Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies

Sponsor

Wuhan Union Hospital, China (Other)

Overall Status

Recruiting

CT.gov ID

NCT04008394

Collaborator

Wuhan Bio-Raid Biotechnology Co, Ltd. China (Other)

Enrollment

Location

Arm

Anticipated Duration (Months)

1.2

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The overall purpose of this study is to explore the safety and therapeutic effect of CD30-targeted chimeric antigen receptor T(CAR-T) cells in the treatment of Refractory/Relapsed lymphocyte malignancies.

Condition or Disease	Intervention/Treatment	Phase
Adult T-Cell Lymphoma/Leukaemia Anaplastic Large Cell Lymphoma Angioimmunoblastic T-cell Lymphoma NK/T-cell Lymphoma Peripheral T Cell Lymphoma Hodgkin Lymphoma	Genetic: Anti-CD30 CAR T cells	Phase 1

Detailed Description

Chimeric antigen receptor (CAR)-modified T cells (CAR-T cells) have the capabilities to recognize tumor associated antigen and kill tumor cells specifically. CD30 is originally described as a marker of Hodgkin's and R-S cells in Hodgkin's lymphoma. CD30 antibody has been applied to treat lymphocyte derived malignancies. To explore the potency of CD30 in CAR-T therapy, this trial is designed and conducted to test the safety and efficacy of CD30-targeted CAR-T in Refractory/Relapsed lymphocyte malignancies.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

50 participants

Allocation:

N/A

Intervention Model:

Single Group Assignment

Intervention Model Description:

Single-center,Open,One-arm Clinical StudySingle-center,Open,One-arm Clinical Study

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

Efficacy and Safety of Anti-CD30 CAR-T Therapy in Patients With Refractory/Relapsed Lymphocyte Malignancies：a Single-center, Open, Single-arm Clinical Study.

Actual Study Start Date :

Jul 3, 2019

Anticipated Primary Completion Date :

Jul 1, 2022

Anticipated Study Completion Date :

Jan 1, 2023

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Anti-CD30 CAR T cells Patients receive CD30 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity. Autologous 3th generation anti-CD30 CAR T cells.	Genetic: Anti-CD30 CAR T cells Patients receive CD30 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity. Autologous 3th generation anti-CD30 CAR T cells.

Arm

Intervention/Treatment

Experimental: Anti-CD30 CAR T cells

Patients receive CD30 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity. Autologous 3th generation anti-CD30 CAR T cells.

Genetic: Anti-CD30 CAR T cells

Patients receive CD30 CAR-T cells transduced with a lentiviral vector on day 0 in the absence of disease progression or unacceptable toxicity. Autologous 3th generation anti-CD30 CAR T cells.

Outcome Measures

Primary Outcome Measures

Number of participants with adverse events [3 years]
Therapy-related adverse events were recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 4.0).

Secondary Outcome Measures

One-month remission rate [1 month]
Response to CAR-T therapy was assessed on day 30 (±2), against the National Comprehensive Cancer Network (NCCN, Version 1.2015).
Overall survival [3 years]
OS was calculated from the first CAR-T cell infusion to death or last follow-up (censored).
Event-free survival [3 years]
EFS was calculated from the first CAR-T cell infusion to death, progression of the disease, relapse or gene recurrence, whichever came first, or last visit (censored).
Relapse-free survival [3 years]
RFS was calculated from the first CAR-T cell infusion to relapse or last visit (censored).
Quantity of anti-CD30 CAR-T cells in bone marrow cells and peripheral blood cells [3 years]
In vivo (bone marrow and peripheral blood) quantity of CAR-T cells were determined by means of flow cytometry.
Quantity of anti-CD30 CAR copies in bone marrow cells and peripheral blood cells [3 years]
In vivo (bone marrow and peripheral blood) quantity of anti-CD30 CAR copies were determined by means of qPCR.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 70 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Patient or his or her legal guardian voluntarily participates in and signs an informed consent form.
Male or female patients aged 18 to 70 years (including 18 and 70 years old).
Pathological and histological examination confirmed CD30+ lymphocyte malignancies, and patients currently have no effective treatment options, such as chemotherapy or recurrence after hematopoietic stem cell transplantation; or patients voluntarily choose Anti-CD30 CAR-T as rescue treatment.
CD30+ lymphocyte malignancies:
Adult T-cell leukemia/lymphoma
Anaplastic large cell lymphoma (ALCL);
Angioimmunoblastic T-cell Lymphoma (AITL);
NK/T-cell lymphoma;
Peripheral T-cell lymphoma (PTCL);
Hodgkin lymphoma;
Subjects:
There are still residual lesions after major treatment, and they are not suitable for HSCT (auto/allo-HSCT);
Recurrence occurs after CR1, and HSCT (auto/allo-HSCT) is not selected or suitable because of self-willingness;
After hematopoietic stem cell transplantation or cellular immunotherapy, the patient suffered relapse or did not remission.
Having a measurable or evaluable lesion.
Patient's main organs function well：
Liver function: ALT/AST < 3 times the upper limit of normal (ULN) and
total bilirubin≤34.2μmol/L
Renal function: Creatinine < 220μmol/L.
Pulmonary function: Indoor oxygen saturation≥95%.
Cardiac Function: Left ventricular ejection fraction (LVEF) ≥40%.
The patients did not receive any anticancer treatments such as chemotherapy, radiotherapy and immunotherapy (such as immunosuppressive drugs) within 4 weeks before admission, and the toxicity related to previous treatments had returned to < 1 level at admission (except for low toxicity such as alopecia).
The patient's peripheral superficial venous blood flow smoothly, which can meet the needs of intravenous drip.
Patient ECOG score≤2, Estimated survival time≥3 months.

Exclusion Criteria:

Women who are pregnant (urine/blood pregnancy test positive) or lactating.
Male or female with a conception plan in the past 1 years.
Patients cannot guarantee effective contraception (condom or contraceptives, etc.) within 1 years after enrollment.
Uncontrolled infectious disease within 4 weeks prior to enrollment.
Active hepatitis B/C virus.
HIV infected patients.
Suffering from a serious autoimmune disease or immunodeficiency disease.
The patient is allergic and is allergic to macromolecular biopharmaceuticals such as antibodies or cytokines.
The patient participated in other clinical trials within 6 weeks prior to enrollment.
Systemic use of hormones within 4 weeks prior to enrollment (except for patients with inhaled corticosteroids).
Have a history of epilepsy or other central nervous system diseases.
Having drug abuse/addiction.
According to the researcher's judgment, the patient has other unsuitable grouping conditions.